Yergali Miyerbekov

Yergali Miyerbekov

Auto-generated profile, based on publicly available information

Yergali Miyerbekov

National Scientific Centre of Surgery, Dept of Anaesthesiology & Intensive Care, Almaty, Kazakhstan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in European Journal of Anaesthesiology
Verified
Journal Article
Closed access
YMY. Miyerbekov
Y. Miyerbekov
VMV. Mutagirov
V. Mutagirov
MBM. Batyrhanov
M. Batyrhanov

30 June 2025 in BULLETIN OF SURGERY IN KAZAKHSTAN
Verified
Journal Article
Closed access
ACAlmaty Sсe «City Cardiological Center»
Almaty Sсe «City Cardiological Center»
Zhanar NurbayZhanar Nurbay
Zhanar Nurbay
MYMiyerbekov Y
Miyerbekov Y
RTRustem Tuleutayev
Rustem Tuleutayev
PMPashimov M
Pashimov M
CMCenter for Molecular Medicine
Center for Molecular Medicine
Background. Surgical replacement of heart valves with mechanical prostheses is a life-saving procedure for patients with valvular defects. Postoperative success depends heavily on the efficacy and safety of anticoagulant therapy. Warfarin remains the primary drug to prevent thrombotic complications in such patients. Despite its efficacy, warfarin requires individualized dosing, long-term monitoring, and careful bleeding risk assessment. It is a leading cause of serious adverse drug reactions, accounting for up to one-third of related hospitalizations and deaths. A pharmacogenetic approach is increasingly important in optimizing warfarin therapy. Gene polymorphisms affect warfarin metabolism and sensitivity, making the study of these factors particularly relevant in underrepresented populations, such as patients of Kazakh nationality. However, there is limited data on warfarin response in this group. Materials and Methods. This is the first study of its kind among Kazakh patients. It includes 310 individuals who underwent mechanical heart valve replacement and received warfarin therapy between 2015 and 2020. The aim was to evaluate the association between genotype, warfarin dose, and complication rates. Results. Patients showed variable coagulation responses, with INR fluctuations and both hemorrhagic and thrombotic complications documented. Risk factors for adverse outcomes were identified, underscoring the importance of individualized dosing and close monitoring. Conclusions. This study highlights the need for genotype-based dose adjustment to improve the safety and effectiveness of warfarin therapy in Kazakh patients after mechanical valve replacement.

1 June 2014 in European Journal of Anaesthesiology
Verified
Journal Article
Closed access
YMY. Miyerbekov
Y. Miyerbekov
GSG. Svyatova
G. Svyatova
TKT. Kuandykov
T. Kuandykov
VMV. Mutagirov
V. Mutagirov
MPM. Pashimov
M. Pashimov

1 June 2014 in European Journal of Anaesthesiology
Verified
Journal Article
Closed access
YMY. Miyerbekov
Y. Miyerbekov
TKT. Kuandykov
T. Kuandykov
VMV. Mutagirov
V. Mutagirov

1 May 2013 in Journal of Clinical Anesthesia
Verified
Journal Article
Closed access
YMYergali Miyerbekov
Yergali Miyerbekov
VMVladimir Mutagirov
Vladimir Mutagirov
MBMukhtar Batyrkhanov
Mukhtar Batyrkhanov

1 October 2023 in BULLETIN OF SURGERY IN KAZAKHSTAN
Verified
Journal Article
Closed access
ABA.A. Baubekov
A.A. Baubekov
TTT.K. Tajibayev
T.K. Tajibayev
YMYe.M. Miyerbekov
Ye.M. Miyerbekov
ASAlmaty National Scientific Center Of Surgery Named After A.N. Syzganov
Almaty National Scientific Center Of Surgery Named After A.N. Syzganov
TET.ZH. Egemberdiev
T.ZH. Egemberdiev
NON.B. Omarov
N.B. Omarov
The aim of the study is to determine the levels of the S100B protein in patients with ischemic stroke and evaluate its relationship with the size of brain tissue damage, stroke severity, and clinical outcomes. Materials and methods.The study included 113 patients with acute ischemic stroke, hospitalized within the first day after its onset and subjected to invasive treatment. 101 men and 12 women were examined, including 32 at the age of 50-60, 64 at the age of 61-70, 17 at the age of 71-80. parameters and degree of functional deviations according to the NIHSS scale. Results. The content of S100B during the initial determination on average for the group significantly exceeded the level determined in the control by 3.22 times (p=0.025). There was a direct dependence of the content of S100B on the size of the stroke. A moderate increase in the indicator on the 3rd day relative to the determined one on the 1st day and a decrease on the 7th day after the development of the stroke were revealed. There was no significant dependence of S100B content on the presence of comorbidities. The influence of the studied parameter on the degree of neurological deficit was determined only in patients with a large stroke size.